Harmony Biosciences (HRMY) Misses Q3 EPS by 9c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Harmony Biosciences (HRMY) Misses Q3 EPS by 9c, Revenues Beat

Harmony Biosciences Reports Third Quarter 2020 Financial Results and Business Updates

November 12, 2020 8:00 AM EST

WAKIX® (pitolisant) Total Revenue of $45.6 Million for Third Quarter of 2020

Differentiated Product Profile Aligns with Unmet Medical Need

On Track to Initiate Phase 2 Trial in Patients with Prader-Willi Syndrome by Year End

Conference Call and Webcast to be held today at 8:30 a.m. Eastern Time

PLYMOUTH MEETING, Penn. and CHICAGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Harmony) (Nasdaq: HRMY), a pharmaceutical company... More